Clinical Trials

Phase 3 Active not recruiting

Burkitt Lymphoma, Down Syndrome, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

NCT04547049 2026-04-09

A Study Comparing Haploidentical Hematopoietic Stem Cell Transplantations (HSCTs) From Young Non-first-degree and Older First-degree Donors in Hematological Malignancies

232 enrolled

Leukemia

NCT07007312 2026-04-09

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

1,300 enrolled

Leukemia, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT06230224 2026-04-08

OLYMPIA-4

216 enrolled

Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

NCT03150693 2026-04-07

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

Phase 3 Suspended

310 enrolled

Lymphoid

Burkitt Lymphoma

NCT07223814 2026-04-06

Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)

875 enrolled

Leukemia, Myeloid, Acute

NCT00931645 2026-04-02

Auto-LLC 2001

Phase 3 Completed

241 enrolled

Phase 3 Active not recruiting

Leukemia, Lymphocytic, Chronic, B-Cell

NCT01190930 2026-03-31

Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma

9,350 enrolled 51 charts

Down Syndrome, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03959085 2026-03-31

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

5,951 enrolled

Burkitt Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Biphenotypic, Acute

NCT06578247 2026-03-31

QuANTUM-WILD

700 enrolled

Phase 3 Not yet recruiting

Leukemia, Leukemia, Myeloid, Acute

NCT07407140 2026-03-25

VAG-3+7-G

300 enrolled